Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...

Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...

BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...

Kangpu Biopharmaceuticals, Ltd. ("Kangpu") today announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National Medical Products Administration (NMPA) ...

Nearly four years after signing its first major partnership with Takeda Pharmaceutical Co. Ltd., Bridgene Biosciences Inc. returned for a second deal with Takeda – this time focused on using its ...

Virginia Cancer Specialists, a respected leader in providing community-based cancer care in Northern VA for more than ...

Neurodevelopmental disorders company GRIN Therapeutics, an affiliate of the Blackstone Life Sciences portfolio company ...

Takeda must have liked what it got from the chemoproteomics work out of BridGene Biosciences. The Tokyo-based drugmaker ...